Somnus Therapeutics Completes Phase I Study Of Sleep Maintenance Drug
Dec 19th 2008Drug InformationSleep / Sleep Disorders
Somnus Therapeutics, Inc., a private specialty pharmaceutical company developing a controlled-release sleep-maintenance therapy, and SkyePharma PLC (LSE:SKP) today announced the completion of the first Phase I study of SKP-1041. Under the terms of the licensing agreement between SkyePharma and Somnus, a US$1 million milestone payment is now payable to SkyePharma.
More: continued here